Learn, Analyse & Invest
only with
only with
+91
Download Orca
Jeevan Scientific Technology Ltd.
Jeevan Scientific
₹ 0.00
0.00 (0.00)%
NSE
BSE
Software & IT Services
Small-cap - With a market cap of ₹1.63 Cr.
| EX-Date | Purpose |
|---|---|
| 23 06 2021 | Audited Results |
| 09 08 2021 | Quarterly Results |
| 08 11 2021 | Quarterly Results |
| 10 11 2021 | Quarterly Results (Revised) |
| 25 11 2021 | Inter alia, to consider and approve : 1. To review the progress on disinvestment of stake in subsidiary companies. 2. Any other matter with the permission of the chair. |
| 14 02 2022 | Quarterly Results |
| 25 03 2022 | Inter alia, to consider and approve : 1. appointment of Dr. G. Venkata Subbarao as Additional Director in the Independent Category subject to approval of the shareholders. 2. To change the designation of Mr. K. Ramakrishna Prasad from Non-Executive, Independent Director to Non-Executive, Non-Independent Director pursuant to reg. 16(1)(b) of SEBI (LODR) Regulations, 2015. 3.To reconstitute Committees of the Board. |
| 30 05 2022 | Dividend & Audited Results |
| 12 08 2022 | Quarterly Results & A.G.M. & Inter alia, to consider:- 3. Re-appointment of Mr. K. Rama Krishna Prasad as Director, Retires by Rotation. 4. Re appointment of M/s. Pavuluri & Co., as Statutory Auditors of the Company. 5. To decide on the day, date, time and venue of Annual General Meeting for FY 2021-22. 6. Notice of 24th Annual General Meeting for the Financial Year 2021-22. 7. Directors Report and annexures for the Financial Year 2021-22. 8. Appointment of Scrutinizer for the e voting process on resolution proposed at the ensuing Annual General Meeting. 9. Any other business with the permission of the Chair. |
| 11 11 2022 | Quarterly Results |
| 08 02 2023 | Quarterly Results |
| 27 03 2023 | Inter alia, to consider and approve :- 1. To provide corporate guarantee to Nayas Laboratories Private Limited, subsidiary Company under Sec 186 of Companies Act, 2013. 2. To consider prior approval of the related party transaction i.e., providing corporate guarantee to Nayas Laboratories Private Limited, subsidiary Company. 3. Any other business with the permission of the Chair. |
| 27 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results |
| 13 11 2023 | Quarterly Results |
| 14 02 2024 | Quarterly Results |
| 08 11 2024 | Quarterly Results |
| 06 02 2025 | Quarterly Results |
| 30 05 2025 | Audited Results |
| 07 08 2025 | Quarterly Results |
| 14 08 2025 | Quarterly Results |
| 15 10 2025 | Inter alia, to consider and approve:- 1. To consider and evaluate a proposal for raising funds through the issuance of one or more instruments, including equity shares, warrants convertible into equity shares, or other securities, by way of preferential issue, private placement or any other permissible mode(s), in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and other applicable laws, subject to necessary approvals including approval of the shareholders and other statutory/regulatory authorities, as may be required. 2. To consider convening a General Meeting of the members of the Company to seek their approval for the aforementioned fund-raising proposal. 3. Any other business with the permission of the Chair. |
| 12 11 2025 | Quarterly Results |
| 30 12 2025 | inter alia, to consider and approve the following: 1. For Allotment of Warrants and Equity Shares on Preferential Basis. 2. Any other business with the permission of the Chair. |
| 02 01 2026 | (Revised) inter alia, to consider and approve the following: 1. For Allotment of Warrants and Equity Shares on Preferential Basis. 2. Any other business with the permission of the Chair. |
News
